Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vericel Corproation (VCEL)

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 856,130
  • Shares Outstanding, K 45,250
  • Annual Sales, $ 117,850 K
  • Annual Income, $ -9,670 K
  • 60-Month Beta 2.88
  • Price/Sales 7.06
  • Price/Cash Flow 91.69
  • Price/Book 7.71

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.06
  • Number of Estimates 4
  • High Estimate -0.02
  • Low Estimate -0.09
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -185.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.84 +21.90%
on 09/04/20
19.64 -7.89%
on 09/17/20
+1.63 (+9.90%)
since 08/21/20
3-Month
12.82 +41.11%
on 06/26/20
19.64 -7.89%
on 09/17/20
+3.24 (+21.82%)
since 06/23/20
52-Week
6.78 +166.81%
on 03/19/20
19.64 -7.89%
on 09/17/20
+2.13 (+13.35%)
since 09/23/19

Most Recent Stories

More News
Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid (concentrate...

VCEL : 18.09 (-4.39%)
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

MediWound Ltd. (Nasdaq: MDWD) (the "MediWound"), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that...

MDWD : 3.71 (+3.63%)
VCEL : 18.09 (-4.39%)
Vericel to Present at Multiple Upcoming Investor Conferences

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences.

VCEL : 18.09 (-4.39%)
Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, will present the latest company...

MS : 46.42 (-2.54%)
VCEL : 18.09 (-4.39%)
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness

MediWound Ltd. (NASDAQ: MDWD) and its U.S. commercial partner Vericel Corporation (NASDAQ: VCEL) today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office...

MDWD : 3.71 (+3.63%)
VCEL : 18.09 (-4.39%)
Global Autologous Cell Therapy Market Outlook to 2025 by Therapy, Application, Source, End User and Geography

, /PRNewswire/ -- The report has been added to offering.

BCLI : 13.98 (-4.18%)
OPXA : 0.97 (-9.35%)
VCEL : 18.09 (-4.39%)
Vericel Reports Second Quarter 2020 Financial Results

Product Revenues of $20.0 Million Reported for the Second Quarter

VCEL : 18.09 (-4.39%)
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories

MYGN : 12.05 (-4.82%)
IDXX : 363.87 (-1.21%)
CNK : 10.50 (-6.00%)
VCEL : 18.09 (-4.39%)
Dump These 4 Toxic Stocks or Sell Short for Timely Profits

Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.

MYGN : 12.05 (-4.82%)
IDXX : 363.87 (-1.21%)
CNK : 10.50 (-6.00%)
VCEL : 18.09 (-4.39%)
Vericel to Present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20, 2020

Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company...

VCEL : 18.09 (-4.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade VCEL with:

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

2nd Resistance Point 19.82
1st Resistance Point 18.96
Last Price 18.09
1st Support Level 17.66
2nd Support Level 17.22

See More

52-Week High 19.64
Last Price 18.09
Fibonacci 61.8% 14.73
Fibonacci 50% 13.21
Fibonacci 38.2% 11.69
52-Week Low 6.78

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar